Are thrombotic risk and progression in ET predictable?

Описание к видео Are thrombotic risk and progression in ET predictable?

Joseph Scandura, MD, PhD, Weill Cornell Medicine, New York, NY, discusses the need to broaden the focus beyond thrombotic risk when managing patients with essential thrombocythemia (ET). Dr Scandura highlights the possibility of predicting composite risk by identifying the specific driver mutation harbored by a patient, as this provides insight into whether they are at greater risk for thrombosis or progression. This interview took place at the 1st Annual MPN Workshop of the Carolinas in Asheville, NC.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Комментарии

Информация по комментариям в разработке

Похожие видео